Cost-effectiveness of brexpiprazole for the treatment of major depressive disorder in Japan
Brexpiprazole, especially when initiated early, was a cost-effective adjunctive treatment for patients with MDD and a history of inadequate response to SSRI/SNRI.
Authors
- Michał Górecki (ORCID: https://orcid.org/0000-0001-9902-0770)
- Michał Pochopień
- Kentaro Yamato
- Mitsuhiro Sado (ORCID: https://orcid.org/0000-0002-2626-8123)
- Yilong Zhang (ORCID: https://orcid.org/0000-0001-6750-7613)
Institutions
- Keio University (JP)
Publication Details
- Journal
- Journal of Affective Disorders
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1016/j.jad.2025.119532
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Otsuka Pharmaceutical